Survival with Provenge - Real World Data Along with A Peek Into the Future of Treatment
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Survival with Provenge - Real World Data Along with A Peek Into the Future of Treatment
-
ナレーター：
-
著者：
このコンテンツについて
Joel T Nowak from Cancer ABCs discusses with Dr. Rana McKay, Associate Professor of Medicine at the Moores Cancer Center at the University of California in San Diego, her recently published article that analysizes real world data that demonstrates that Provenge (sipuleucel-T), an immune therapy for castrate resistant metastatic prostate cancer (mCRPC), can reduce the risk of death over and above the newer hormone treatments that have been FDA approved .
Dr, McKay evaluated a large medicare data base and determined that despite the addition of the many second generation hormone treatments like Zytiga and Xtandi, Provenge continues to lower the risk of death for men with mCRPC.
Dr. Mckay also shared a peek into the future of additional immune therapies for prostate cancer as well as sharing information about the newly FDA approved part inhibitors.
Cancer ABCs would like to thank its podcast sponsors for their support of this podcast program. Our sponsors include:
- Myovant/Pfizer
- Foundation Medicine
- Bayer
- Dendreon